$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw

$avrw Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000147793224003092 Filed on May 17, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$287.0K	$1.122M	$4.347M
YoY Change	-70.47%		-11.21%
Cost Of Revenue	$58.00K	$421.0K	$1.238M
YoY Change	-79.14%		-20.49%
Gross Profit	$229.0K	$701.0K	$3.109M
YoY Change	-67.0%		-6.89%
Gross Profit Margin	79.79%	62.48%	71.52%
Selling, General & Admin	$944.0K	$1.670M	$9.120M
YoY Change	-62.86%		-22.22%
% of Gross Profit	412.23%	238.23%	293.34%
Research & Development			$0.00
YoY Change			-100.0%
% of Gross Profit			0.0%
Depreciation & Amortization	$1.000K	$21.00K	$1.000K
YoY Change	0.0%		0.0%
% of Gross Profit	0.44%	3.0%	0.03%
Operating Expenses	$944.0K	$1.455M	$8.615M
YoY Change	-56.89%		-60.13%
Operating Profit	-$715.0K	-$754.0K	-$5.506M
YoY Change	-52.21%		-69.86%
Interest Expense	-$5.000K	-$6.000K	$44.00K
YoY Change	-138.46%		0.0%
% of Operating Profit
Other Income/Expense, Net	-$179.0K	-$397.0K	$2.065M
YoY Change	-135.17%		-1005.7%
Pretax Income	-$894.0K	-$21.00K	-$3.441M
YoY Change	-9.42%		-81.4%
Income Tax	$3.000K	$3.000K	-$3.000K
% Of Pretax Income
Net Earnings	-$897.0K	-$24.00K	-$3.444M
YoY Change	-9.12%		-86.5%
Net Earnings / Revenue	-312.54%	-2.14%	-79.23%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.01	$0.00	-$0.05
COMMON SHARES
Basic Shares Outstanding	77.99M shares	73.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.00K	$49.00K	$49.00K
YoY Change	-89.14%		-98.34%
Cash & Equivalents	$19.00K	$49.00K
Short-Term Investments
Other Short-Term Assets	$7.000K	$69.00K	$286.0K
YoY Change	-85.11%	18.97%	-35.15%
Inventory	$151.0K	$199.0K	$199.0K
Prepaid Expenses	$15.00K	$33.00K
Receivables	$49.00K	$443.0K	$443.0K
Other Receivables	$0.00	$979.0K	$979.0K
Total Short-Term Assets	$320.0K	$1.956M	$1.956M
YoY Change	-88.66%	-67.0%	-67.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.000K	$4.000K	$54.00K
YoY Change	0.0%	0.0%	-67.07%
Goodwill
YoY Change
Intangibles	$218.0K	$227.0K
YoY Change		-6.97%
Long-Term Investments	$264.0K	$264.0K	$264.0K
YoY Change	-35.77%		-35.77%
Other Assets	$36.00K	$36.00K	$36.00K
YoY Change	0.0%		0.0%
Total Long-Term Assets	$710.0K	$651.0K	$651.0K
YoY Change	-20.05%	-29.7%	-29.7%
TOTAL ASSETS
Total Short-Term Assets	$320.0K	$1.956M	$1.956M
Total Long-Term Assets	$710.0K	$651.0K	$651.0K
Total Assets	$1.030M	$2.607M	$2.607M
YoY Change	-72.24%	-61.96%	-61.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.283M	$2.452M	$2.452M
YoY Change	79.91%	130.23%	130.23%
Accrued Expenses	$1.453M	$1.342M	$1.387M
YoY Change	-1.42%	-15.33%	-18.84%
Deferred Revenue
YoY Change
Short-Term Debt	$67.00K	$139.0K	$139.0K
YoY Change	-88.55%		-80.45%
Long-Term Debt Due	$8.694M	$8.099M	$8.099M
YoY Change	20.73%		-11.78%
Total Short-Term Liabilities	$12.97M	$12.49M	$12.49M
YoY Change	12.01%	-10.21%	-10.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$74.00K	$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$74.00K	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.97M	$12.49M	$12.49M
Total Long-Term Liabilities	$74.00K	$0.00	$0.00
Total Liabilities	$13.04M	$12.49M	$12.49M
YoY Change	12.65%	-10.5%	-10.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.6M	-$123.4M
YoY Change	3.66%	2.87%
Common Stock	$78.00K	$78.00K
YoY Change	8.33%	9.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.01M	-$9.886M	-$9.886M
YoY Change
Total Liabilities & Shareholders Equity	$1.030M	$2.607M	$2.607M
YoY Change	-72.24%	-61.96%	-61.96%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$897.0K	-$24.00K	-$3.444M
YoY Change	-9.12%		-86.5%
Depreciation, Depletion And Amortization	$1.000K	$21.00K	$1.000K
YoY Change	0.0%		0.0%
Cash From Operating Activities	-$314.0K	-$524.0K	-$3.843M
YoY Change	-73.68%		-61.85%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$3.000K	$2.000K
YoY Change	-100.0%		100.0%
Acquisitions
YoY Change
Other Investing Activities	$360.0K	$275.0K	$1.025M
YoY Change			-92.59%
Cash From Investing Activities	$360.0K	$272.0K	$971.0K
YoY Change	-4100.0%		-92.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-56.00K	112.0K	-$22.00K
YoY Change	-11.11%		-97.37%
NET CHANGE
Cash From Operating Activities	-314.0K	-524.0K	-$3.843M
Cash From Investing Activities	360.0K	272.0K	$971.0K
Cash From Financing Activities	-56.00K	112.0K	-$22.00K
Net Change In Cash	-10.00K	-140.0K	-$2.894M
YoY Change	-99.21%		-198.87%
FREE CASH FLOW
Cash From Operating Activities	-$314.0K	-$524.0K	-$3.843M
Capital Expenditures	$0.00	$3.000K	$2.000K
Free Cash Flow	-$314.0K	-$527.0K	-$3.845M
YoY Change	-73.88%		-61.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Other Assets OtherAssets	36000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160000	usd
CY2022Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	2000000	usd
CY2022Q4	us-gaap	Investments Investments	411000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2943000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	232000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5928000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001643301
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71426801	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77993348	shares
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	0	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-204857
CY2023	dei	Entity Registrant Name EntityRegistrantName	AVENIR WELLNESS SOLUTIONS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-1504639
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5805 Sepulveda Boulevard
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Sherman Oaks
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91411
CY2023	dei	City Area Code CityAreaCode	424
CY2023	dei	Local Phone Number LocalPhoneNumber	273-8675
CY2023	dei	Security12g Title Security12gTitle	Common stock, par value $0.001
CY2023	dei	Trading Symbol TradingSymbol	AVRW
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5700000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77993348	shares
CY2023	dei	Auditor Firm AuditorFirmId	1013
CY2023	dei	Auditor Name AuditorName	Urish Popeck & Co., LLC
CY2023	dei	Auditor Location AuditorLocation	Pittsburgh, Pennsylvania
CY2023Q4	avrw	Due From Related Party DueFromRelatedParty	4000	usd
CY2022Q4	avrw	Due From Related Party DueFromRelatedParty	167000	usd
CY2023Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	975000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	199000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	145000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	244000	usd
CY2023Q4	avrw	Customer Relationships Trade Name And Non Compete Agreements Net CustomerRelationshipsTradeNameAndNonCompeteAgreementsNet	70000	usd
CY2022Q4	avrw	Customer Relationships Trade Name And Non Compete Agreements Net CustomerRelationshipsTradeNameAndNonCompeteAgreementsNet	71000	usd
CY2022Q4	us-gaap	Assets Assets	6854000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2452000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1065000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1342000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1585000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	124000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	139000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	161000	usd
CY2023Q4	avrw	Convertible Promissory Notes ConvertiblePromissoryNotes	0	usd
CY2022Q4	avrw	Convertible Promissory Notes ConvertiblePromissoryNotes	550000	usd
CY2023Q4	avrw	Fair Value Convertible Promissory Notes Net FairValueConvertiblePromissoryNotesNet	8099000	usd
CY2022Q4	avrw	Fair Value Convertible Promissory Notes Net FairValueConvertiblePromissoryNotesNet	9180000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	416000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	388000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	860000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12493000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13913000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	46000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	12493000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13959000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77993348	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71426801	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	78000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	71000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	113435000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	112471000	usd
CY2023Q4	us-gaap	Common Unit Issuance Value CommonUnitIssuanceValue	0	usd
CY2022Q4	us-gaap	Common Unit Issuance Value CommonUnitIssuanceValue	308000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123399000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119955000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9886000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7105000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2607000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6854000	usd
CY2023	avrw	Rvenue From Product Sales Net Of Discounts And Refunds RvenueFromProductSalesNetOfDiscountsAndRefunds	4258000	usd
CY2022	avrw	Rvenue From Product Sales Net Of Discounts And Refunds RvenueFromProductSalesNetOfDiscountsAndRefunds	2891000	usd
CY2023	avrw	Revenue From Product Sales Through Related Party RevenueFromProductSalesThroughRelatedParty	89000	usd
CY2022	avrw	Revenue From Product Sales Through Related Party RevenueFromProductSalesThroughRelatedParty	2005000	usd
CY2023	us-gaap	Revenues Revenues	4347000	usd
CY2022	us-gaap	Revenues Revenues	4896000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1238000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1557000	usd
CY2023	us-gaap	Gross Profit GrossProfit	3109000	usd
CY2022	us-gaap	Gross Profit GrossProfit	3339000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9120000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11725000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	4690000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	5764000	usd
CY2023	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-505000	usd
CY2022	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-570000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	8615000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21609000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18270000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	73000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1136000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	90000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-17000	usd
CY2023	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	1081000	usd
CY2022	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	85000	usd
CY2023	avrw	Reserve On Investment ReserveOnInvestment	-147000	usd
CY2022	avrw	Reserve On Investment ReserveOnInvestment	-71000	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	57000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	465000	usd
CY2023	us-gaap	Other Income OtherIncome	0	usd
CY2022	us-gaap	Other Income OtherIncome	26000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2065000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-228000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18498000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3444000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18540000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	0	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-6404000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-565000	usd
CY2023	us-gaap	Discontinued Operation Tax Expense Benefit From Provision For Gain Loss On Disposal DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal	0	usd
CY2022	us-gaap	Discontinued Operation Tax Expense Benefit From Provision For Gain Loss On Disposal DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal	0	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-6969000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3444000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-25509000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.26
CY2023	avrw	Discontinued Operation Gain Loss Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationGainLossDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0
CY2022	avrw	Discontinued Operation Gain Loss Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationGainLossDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.10
CY2023	avrw	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.05
CY2022	avrw	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.36
CY2023	avrw	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	72091716000	shares
CY2022	avrw	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	70205544000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16112000	usd
CY2022	avrw	Issuance Of Common Stock For Professional Services Amount IssuanceOfCommonStockForProfessionalServicesAmount	38000	usd
CY2022	avrw	Issuance Of Common Stock Pursuant To Vested Restricted Stock Units Amount IssuanceOfCommonStockPursuantToVestedRestrictedStockUnitsAmount	0	usd
CY2022	avrw	Issuance Of Restricted Stock Amount IssuanceOfRestrictedStockAmount	216000	usd
CY2022	avrw	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	420000	usd
CY2022	avrw	Fair Value Of Stock Options Vested FairValueOfStockOptionsVested	952000	usd
CY2022	avrw	Issuance Of Common Stock For Conversion Of Convertible Promissory Notes Amount IssuanceOfCommonStockForConversionOfConvertiblePromissoryNotesAmount	666000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-25509000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7105000	usd
CY2023	avrw	Issuance Of Common Stock For Professional Services Amount IssuanceOfCommonStockForProfessionalServicesAmount	44000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	355000	usd
CY2023	avrw	Issuance Of Restricted Stock Units Amount IssuanceOfRestrictedStockUnitsAmount	0	usd
CY2023	avrw	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	300000	usd
CY2023	avrw	Fair Value Of Stock Options Vested FairValueOfStockOptionsVested	272000	usd
CY2023	avrw	Expired Stock Payable ExpiredStockPayable	-308000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3444000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9886000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3444000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18540000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-6969000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3444000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-25509000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-565000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	44000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7000	usd
CY2023	avrw	Gain Loss On Settlement Of Accounts Payable GainLossOnSettlementOfAccountsPayable	0	usd
CY2022	avrw	Gain Loss On Settlement Of Accounts Payable GainLossOnSettlementOfAccountsPayable	83000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1136000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	90000	usd
CY2023	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-505000	usd
CY2022	avrw	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-570000	usd
CY2023	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	1081000	usd
CY2022	avrw	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	85000	usd
CY2023	avrw	Reserve On Investment ReserveOnInvestment	-147000	usd
CY2022	avrw	Reserve On Investment ReserveOnInvestment	-71000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	72000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1481000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	4690000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	5764000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	110000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	97000	usd
CY2023	avrw	Recovery Of Bad Debt Expense RecoveryOfBadDebtExpense	0	usd
CY2022	avrw	Recovery Of Bad Debt Expense RecoveryOfBadDebtExpense	-35000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	-70000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	253000	usd
CY2023	avrw	Fair Value Of Vested Stock Options And Restricted Stock FairValueOfVestedStockOptionsAndRestrictedStock	-572000	usd
CY2022	avrw	Fair Value Of Vested Stock Options And Restricted Stock FairValueOfVestedStockOptionsAndRestrictedStock	-1619000	usd
CY2023	avrw	Debt Conversion Originaldiscount DebtConversionOriginaldiscount	0	usd
CY2022	avrw	Debt Conversion Originaldiscount DebtConversionOriginaldiscount	-33000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	211000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-160000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-16000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-312000	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-163000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	167000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-155000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	96000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	69000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1387000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1661000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	35000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1858000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-125000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-108000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	28000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	95000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-5111000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3843000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10073000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	53000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	52000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	13891000	usd
CY2023	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	1025000	usd
CY2022	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	971000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13837000	usd
CY2023	avrw	Proceeds From Notes Payable Of Disposal Group ProceedsFromNotesPayableOfDisposalGroup	0	usd
CY2022	avrw	Proceeds From Notes Payable Of Disposal Group ProceedsFromNotesPayableOfDisposalGroup	3702000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3935000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6347000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	190000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2243000	usd
CY2023	avrw	Proceeds From Loans Payable ProceedsFromLoansPayable	0	usd
CY2022	avrw	Proceeds From Loans Payable ProceedsFromLoansPayable	161000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	22000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	235000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-22000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-837000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2894000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2927000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2943000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2943000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	585000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	avrw	Repayment Of Buyer Advances RepaymentOfBuyerAdvances	0	usd
CY2022	avrw	Repayment Of Buyer Advances RepaymentOfBuyerAdvances	-4150000	usd
CY2023	avrw	Write Off Convertible Promissory Notes And Accrued Interest WriteOffConvertiblePromissoryNotesAndAccruedInterest	-828000	usd
CY2022	avrw	Write Off Convertible Promissory Notes And Accrued Interest WriteOffConvertiblePromissoryNotesAndAccruedInterest	0	usd
CY2023	avrw	Write Off Common Stock Payable WriteOffCommonStockPayable	-308000	shares
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	-355000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	usd
CY2023	avrw	Common Stock Issued For Conversion Of Promissory Notes And Accrued Interest CommonStockIssuedForConversionOfPromissoryNotesAndAccruedInterest	0	usd
CY2022	avrw	Common Stock Issued For Conversion Of Promissory Notes And Accrued Interest CommonStockIssuedForConversionOfPromissoryNotesAndAccruedInterest	666000	usd
CY2023	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	usd
CY2022	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	213000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	42000	usd
CY2023Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	123400000	usd
CY2023Q4	avrw	Working Capital Deficit WorkingCapitalDeficit	10500000	usd
CY2023Q4	us-gaap	Cash Cash	49000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include, but are not limited to, the allowance for doubtful accounts, valuation of intangible assets and goodwill, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent stock consideration, stock based compensation, beneficial conversion features, warrant values, valuation allowance on deferred taxes, incremental borrowing rate (“IBR”) relating to leases, assumption used for discounts and returns in relation to revenue and the assumptions used to calculate derivative liabilities and fair values of the purchase price allocations and convertible promissory notes. Actual results could differ materially from such estimates under different assumptions or circumstances. </p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2400000	usd
CY2022	avrw	Additions To Contract Liabilities AdditionsToContractLiabilities	155000	usd
CY2023	avrw	Impairment Loss On Goodwill From Continuing Operation ImpairmentLossOnGoodwillFromContinuingOperation	0	usd
CY2022	avrw	Impairment Loss On Goodwill From Continuing Operation ImpairmentLossOnGoodwillFromContinuingOperation	4700000	usd
CY2023	avrw	Impairment Loss On Goodwill From Discontinued Operation ImpairmentLossOnGoodwillFromDiscontinuedOperation	0	usd
CY2022	avrw	Impairment Loss On Goodwill From Discontinued Operation ImpairmentLossOnGoodwillFromDiscontinuedOperation	4700000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	5800000	usd
CY2023	avrw	Related Partiespolicytextblock RelatedPartiespolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.</p>
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	293000	usd
CY2022	avrw	Contract Liabilities Customer Deposits Returned ContractLiabilitiesCustomerDepositsReturned	0	usd
CY2022	avrw	Contract Liabilities Transfers To Revenue ContractLiabilitiesTransfersToRevenue	-146000	usd
CY2022	avrw	Contract Liabilities Held For Sale ContractLiabilitiesHeldForSale	193000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	495000	usd
CY2023	avrw	Additions To Contract Liabilities AdditionsToContractLiabilities	93000	usd
CY2023	avrw	Contract Liabilities Customer Deposits Returned ContractLiabilitiesCustomerDepositsReturned	0	usd
CY2023	avrw	Contract Liabilities Transfers To Revenue ContractLiabilitiesTransfersToRevenue	-172000	usd
CY2023	avrw	Contract Liabilities Held For Sale ContractLiabilitiesHeldForSale	0	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	416000	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2800000	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2200000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	492000	usd
CY2023Q4	avrw	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	408000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	420000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	492000	usd
CY2023Q4	avrw	Fair Value Of Contingent Stock Consideration FairValueOfContingentStockConsideration	0	usd
CY2023Q4	avrw	Fair Value Of Series A Note FairValueOfSeriesANote	4597000	usd
CY2023Q4	avrw	Fair Value Of Series B Note FairValueOfSeriesBNote	3502000	usd
CY2022Q4	avrw	Fair Value Of Contingent Stock Consideration FairValueOfContingentStockConsideration	860000	usd
CY2022Q4	avrw	Fair Value Of Series A Note FairValueOfSeriesANote	5221000	usd
CY2022Q4	avrw	Fair Value Of Series B Note FairValueOfSeriesBNote	3959000	usd
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	9932000	usd
CY2022	avrw	Changes In Fair Value Of Series A Note ChangesInFairValueOfSeriesANote	2146000	usd
CY2022	avrw	Change In Fair Value Of Series B Notes ChangeInFairValueOfSeriesBNotes	-2232000	usd
CY2022	avrw	Conversion Of Series A Notes ConversionOfSeriesANotes	0	usd
CY2022	avrw	Conversion Of Series B Notes ConversionOfSeriesBNotes	-666000	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	9180000	usd
CY2023	avrw	Changes In Fair Value Of Series A Note ChangesInFairValueOfSeriesANote	-624000	usd
CY2023	avrw	Change In Fair Value Of Series B Notes ChangeInFairValueOfSeriesBNotes	-457000	usd
CY2023Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	8099000	usd
CY2023	avrw	Stock Price StockPrice	0.0744
CY2022	avrw	Stock Price StockPrice	0.25
CY2023	avrw	Conversion Price ConversionPrice	1.32
CY2022	avrw	Conversion Price ConversionPrice	1.32
CY2023	avrw	Interest Rate InterestRate	0.180	pure
CY2022	avrw	Interest Rate InterestRate	0.180	pure
CY2023	avrw	Gain Loss From Change In Fair Value Of Series A And B Convertible Notes GainLossFromChangeInFairValueOfSeriesAAndBConvertibleNotes	1100000	usd
CY2022	avrw	Gain Loss From Change In Fair Value Of Series A And B Convertible Notes GainLossFromChangeInFairValueOfSeriesAAndBConvertibleNotes	85000	usd
CY2023	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity,” then in accordance with ASC 815-40, "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock." Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. The Company does not have any liability classified warrants as of any period presented.</p>
CY2023	avrw	Vested Stock Options From The Companys Equity Incentive Plan VestedStockOptionsFromTheCompanysEquityIncentivePlan	1425324	shares
CY2022	avrw	Vested Stock Options From The Companys Equity Incentive Plan VestedStockOptionsFromTheCompanysEquityIncentivePlan	1107980	shares
CY2023	avrw	Warrants Shares WarrantsShares	312500	shares
CY2022	avrw	Warrants Shares WarrantsShares	312500	shares
CY2022	avrw	Shares To Be Issued Upon Conversion Of Convertible Payable SharesToBeIssuedUponConversionOfConvertiblePayable	416667	shares
CY2023	avrw	Anti Dilutive Shares AntiDilutiveShares	1737824	shares
CY2022	avrw	Anti Dilutive Shares AntiDilutiveShares	1837147	shares
CY2022Q4	us-gaap	Inventory Gross InventoryGross	508000	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	-293000	usd
CY2023Q4	avrw	Customer Billed Accounts Receivable CustomerBilledAccountsReceivable	443000	usd
CY2022Q4	avrw	Customer Billed Accounts Receivable CustomerBilledAccountsReceivable	232000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	443000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	232000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	184000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	207000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	176000	usd
CY2023Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0	usd
CY2022Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	29000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	69000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	29000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	286000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	441000	usd
CY2023Q4	avrw	Inventory Packaging Components InventoryPackagingComponents	84000	usd
CY2022Q4	avrw	Inventory Packaging Components InventoryPackagingComponents	88000	usd
CY2022Q4	us-gaap	Inventory Adjustments InventoryAdjustments	-363000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	199000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	145000	usd
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	88000	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	359000	usd
CY2023Q4	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	5000	usd
CY2022Q4	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	4000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2023	us-gaap	Depreciation Depreciation	1000	usd
CY2022	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	62000	usd
CY2022Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	33000	usd
CY2023Q4	avrw	Less Current Portion Of Notes Receivable LessCurrentPortionOfNotesReceivable	-975000	usd
CY2022Q4	avrw	Less Current Portion Of Notes Receivable LessCurrentPortionOfNotesReceivable	-2000000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	0	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	141000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	90000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	71000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	70000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	71000	usd
CY2022Q2	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	4600000	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	4700000	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1100000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10400000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	72000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	68000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	35000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	19000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	18000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	17000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	140000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	297000	usd
CY2023Q4	avrw	Investment In Biopharmaceutical Research Company InvestmentInBiopharmaceuticalResearchCompany	213000	usd
CY2022Q4	avrw	Investment In Biopharmaceutical Research Company InvestmentInBiopharmaceuticalResearchCompany	213000	usd
CY2023Q4	us-gaap	Investments Investments	264000	usd
CY2022Q4	us-gaap	Investments Investments	411000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	568000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	421000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.18	pure
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2023	avrw	Unrecognized Compensation Expense UnrecognizedCompensationExpense	64000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	566000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	551000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	233000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	205000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	82000	usd
CY2023Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	81000	usd
CY2022Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	64000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	154000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	217000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	336000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	331000	usd
CY2023Q4	avrw	Accrued Expenses Current Net AccruedExpensesCurrentNet	1342000	usd
CY2022Q4	avrw	Accrued Expenses Current Net AccruedExpensesCurrentNet	1478000	usd
CY2023	avrw	Interest Expenses For Related Parties InterestExpensesForRelatedParties	0	usd
CY2022	avrw	Interest Expenses For Related Parties InterestExpensesForRelatedParties	111000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	139000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	161000	usd
CY2023Q4	avrw	Loan Payable Less Current Portion LoanPayableLessCurrentPortion	0	usd
CY2022Q4	avrw	Loan Payable Less Current Portion LoanPayableLessCurrentPortion	0	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	6000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	12000	usd
CY2023	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	In addition, the placement agent received a warrant (the “Warrant”) exercisable for two years for the purchase of an aggregate of up to 242,424 shares of the Company’s common stock, at an exercise price of $1.32 per share. The Warrant may also be exercised by means of a “cashless exercise” or “net exercise.” Upon the achievement of certain milestones, the placement agent is entitled to receive an additional warrant, on the same terms as the Warrant, exercisable for an aggregate of up to 363,636 shares of the Company’s common stock (collectively with the shares underlying the Warrant, the “Warrant Shares”). The Warrant Shares, when issued, will have the same rights
CY2023	avrw	Warrant Life In Years WarrantLifeInYears	two years
CY2023Q4	avrw	Warranty Exercise Price Per Share WarrantyExercisePricePerShare	1.32
CY2023Q4	avrw	Convertible Promissory Notes ConvertiblePromissoryNotes	0	usd
CY2022Q4	avrw	Convertible Promissory Notes ConvertiblePromissoryNotes	550000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	550000	usd
CY2023	us-gaap	Interest Expense InterestExpense	44000	usd
CY2022	us-gaap	Interest Expense InterestExpense	44000	usd
CY2023Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	4597000	usd
CY2022Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	5221000	usd
CY2023Q4	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	3502000	usd
CY2022Q4	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	3959000	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	8099000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	9180000	usd
CY2023Q4	avrw	Less Investor Note Offset LessInvestorNoteOffset	0	usd
CY2022Q4	avrw	Less Investor Note Offset LessInvestorNoteOffset	0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8099000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9180000	usd
CY2023Q4	avrw	Less Current Portion Of Convertible Promissory Notes At Fair Value LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue	-8099000	usd
CY2022Q4	avrw	Less Current Portion Of Convertible Promissory Notes At Fair Value LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue	-9180000	usd
CY2023	us-gaap	Debt Conversion Description DebtConversionDescription	The Investor will not have the right to convert any portion of a Convertible Notes, to the extent that, after giving effect to such conversion, the Investor (and other certain related parties) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion. This limit may, from time to time, be increased, up to 9.99%, or decreased
CY2023	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	8700000	usd
CY2023	avrw	Warrant Exercisable Shares WarrantExercisableShares	4096272	shares
CY2023	avrw	Remaining Balance Of Investor Note RemainingBalanceOfInvestorNote	8500000	usd
CY2023	avrw	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding And Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingAndExercisable	0	usd
CY2022	avrw	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding And Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingAndExercisable	0	usd
CY2023	avrw	Term Of Exercise Period TermOfExercisePeriod	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	80000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	272000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000.0	usd
CY2023	avrw	Weighted Average Remaining Contractual Life Year WeightedAverageRemainingContractualLifeYear	P1Y5M1D
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	avrw	Common Stock Issued During Period Price Per Share CommonStockIssuedDuringPeriodPricePerShare	0.19
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	4790419	shares
CY2023	avrw	Common Stock Issued During Period Price Per Share CommonStockIssuedDuringPeriodPricePerShare	0.074
CY2023	avrw	Marginal Tax Rate MarginalTaxRate	0.21	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	49000000	usd
CY2023	avrw	Net Operating Loss Carryforward Expire NetOperatingLossCarryforwardExpire	12400000	usd
CY2023	avrw	Net Operating Loss Carryforwards Expiration Date NetOperatingLossCarryforwardsExpirationDate	2038
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	36600000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	39000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	42000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	avrw	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	3000	usd
CY2022	avrw	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	42000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10043000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7581000	usd
CY2023Q4	avrw	Changes In Fair Value Of Convertible Promissory Notes ChangesInFairValueOfConvertiblePromissoryNotes	-233000	usd
CY2022Q4	avrw	Changes In Fair Value Of Convertible Promissory Notes ChangesInFairValueOfConvertiblePromissoryNotes	1358000	usd
CY2023Q4	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	1317000	usd
CY2022Q4	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	1181000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	123000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	114000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	57000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	98000	usd
CY2023Q4	avrw	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	-5000	usd
CY2022Q4	avrw	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3000	usd
CY2023Q4	avrw	Deferred Tax Assets Other Intangibles DeferredTaxAssetsOtherIntangibles	-418000	usd
CY2022Q4	avrw	Deferred Tax Assets Other Intangibles DeferredTaxAssetsOtherIntangibles	-423000	usd
CY2023Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	87000	usd
CY2022Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	124000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	104000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	94000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	116000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	116000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	11191000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	10246000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	79000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	172000	usd
CY2023Q4	avrw	Deferred Income Tax Liabilities Depreciation And Amortization DeferredIncomeTaxLiabilitiesDepreciationAndAmortization	22000	usd
CY2022Q4	avrw	Deferred Income Tax Liabilities Depreciation And Amortization DeferredIncomeTaxLiabilitiesDepreciationAndAmortization	-19000	usd
CY2023Q4	avrw	Deferred Tax Liabilities Valuation Allowance DeferredTaxLiabilitiesValuationAllowance	11134000	usd
CY2022Q4	avrw	Deferred Tax Liabilities Valuation Allowance DeferredTaxLiabilitiesValuationAllowance	10055000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11191000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10246000	usd
CY2023Q4	avrw	Deferred Income Tax Net DeferredIncomeTaxNet	0	usd
CY2022Q4	avrw	Deferred Income Tax Net DeferredIncomeTaxNet	0	usd
CY2023Q4	avrw	Ownership Interest OwnershipInterest	0.50	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	1	pure
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1100000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	816000	usd
CY2023	avrw	Description Of Lease Agreement DescriptionOfLeaseAgreement	the lease agreement (the “Lease”) expired on April 30, 2024. The Company has entered into a new two-year lease with its current landlord for 2,902 square feet of office space in the existing building which expires on April 30, 2026. The lease provides for the payment of base monthly rent in the amount of $7 thousand during the first 12 months of the term with annual increases, over the base monthly rent then in effect, by 3%
CY2023	avrw	Weighted Average Discount Rate In Percentage WeightedAverageDiscountRateInPercentage	0.1130	pure
CY2023Q4	avrw	Operating Lease Liabilities Current OperatingLeaseLiabilitiesCurrent	45000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	46000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	0	usd
CY2023Q4	avrw	Lessor Operating Lease Payments Undiscounted Cash Flow LessorOperatingLeasePaymentsUndiscountedCashFlow	46000	usd
CY2023Q4	us-gaap	Other Commitment OtherCommitment	1000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	45000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160000	usd
CY2023Q4	avrw	Right Of Use Lease Liabilities Current RightOfUseLeaseLiabilitiesCurrent	45000	usd
CY2022Q4	avrw	Right Of Use Lease Liabilities Current RightOfUseLeaseLiabilitiesCurrent	124000	usd
CY2023Q4	avrw	Right Of Use Lease Liability Noncurrent RightOfUseLeaseLiabilityNoncurrent	0	usd
CY2022Q4	avrw	Right Of Use Lease Liability Noncurrent RightOfUseLeaseLiabilityNoncurrent	46000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	45000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	170000	usd
CY2022	avrw	Weighted Average Remaining Lease Term Operating Lease WeightedAverageRemainingLeaseTermOperatingLease	P0Y3M14D
CY2023	avrw	Weighted Average Remaining Lease Term Operating Lease WeightedAverageRemainingLeaseTermOperatingLease	P1Y3M14D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.113	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.113	pure
CY2020Q4	us-gaap	Cash Cash	1000000	usd
CY2023	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	5988024	shares
CY2021Q4	avrw	Fair Value Of Contingent Stock Consideration FairValueOfContingentStockConsideration	1430000	usd
CY2022	avrw	Change In Fair Value Of Contingent Stocks Consideration ChangeInFairValueOfContingentStocksConsideration	-570000	usd
CY2022Q4	avrw	Fair Value Of Contingent Stock Consideration FairValueOfContingentStockConsideration	860000	usd
CY2023	avrw	Change In Fair Value Of Contingent Stocks Consideration ChangeInFairValueOfContingentStocksConsideration	-505000	usd
CY2023	avrw	Issuanceofshares Issuanceofshares	-355000	shares
CY2023Q4	avrw	Fair Value Of Contingent Stock Consideration FairValueOfContingentStockConsideration	0	usd
CY2022Q3	avrw	Consideration Paid For Asset Sale ConsiderationPaidForAssetSale	20000000	usd
CY2022Q3	avrw	Cancellation Of Indebtedness Owed By The Company To Buyer In Amount Equal CancellationOfIndebtednessOwedByTheCompanyToBuyerInAmountEqual	4150000	usd
CY2022Q3	avrw	Cash Reduced By Assumed Liabilities CashReducedByAssumedLiabilities	41000	usd
CY2022Q3	avrw	Retained Other Patents Not Included In The Asset Sale RetainedOtherPatentsNotIncludedInTheAssetSale	15	integer
CY2023	avrw	Net Cash Received From The Asset Sales Price NetCashReceivedFromTheAssetSalesPrice	20000000	usd
CY2023	avrw	Net Cash Received From The Asset Sales Forgiveness Of Buyer Advances NetCashReceivedFromTheAssetSalesForgivenessOfBuyerAdvances	-4150000	usd
CY2023	avrw	Net Cash Received From The Asset Sales Holdback Secured Promissory Note NetCashReceivedFromTheAssetSalesHoldbackSecuredPromissoryNote	-2000000	usd
CY2023	avrw	Net Cash Received From The Asset Sales Obligations Assumed By Buyer NetCashReceivedFromTheAssetSalesObligationsAssumedByBuyer	-41000	usd
CY2023	avrw	Net Cash Received From The Asset Sales Buyers Expense To Be Paid By Seller NetCashReceivedFromTheAssetSalesBuyersExpenseToBePaidBySeller	82000	usd
CY2023	avrw	Net Cash Received From The Asset Sales NetCashReceivedFromTheAssetSales	13891000	usd
CY2023	avrw	Sales Price For Assets Sold SalesPriceForAssetsSold	20000000	usd
CY2023Q4	avrw	Net Book Value Of Assets Sold NetBookValueOfAssetsSold	20616000	usd
CY2023Q4	avrw	Net Book Value Of Liabilities Sold NetBookValueOfLiabilitiesSold	-51000	usd
CY2023Q4	avrw	Net Book Value Of Net Assets Sold NetBookValueOfNetAssetsSold	20565000	usd
CY2023	avrw	Gain Loss On Sale Of Net Assets GainLossOnSaleOfNetAssets	-565000	usd
CY2022Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	20600000	usd
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	4000000	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities	3400000	usd
	avrw	Consideration To Be Received From The Buyer ConsiderationToBeReceivedFromTheBuyer	20000000	usd
	avrw	Additional Impairment Loss AdditionalImpairmentLoss	2000000	usd
CY2022Q2	avrw	Estimated Costs To Sell Charged To Goodwill EstimatedCostsToSellChargedToGoodwill	100000	usd
CY2021Q4	avrw	Inventory Net Assets Held For Sale InventoryNetAssetsHeldForSale	243000	usd
CY2021Q4	avrw	Prepaid Expense And Other Assets Current Assets Held For Sale PrepaidExpenseAndOtherAssetsCurrentAssetsHeldForSale	97000	usd
CY2021Q4	avrw	Property Plant And Equipment Net Assets Held For Sale PropertyPlantAndEquipmentNetAssetsHeldForSale	1837000	usd
CY2021Q4	avrw	Finance Lease Right Of Use Asset Assets Held For Sale FinanceLeaseRightOfUseAssetAssetsHeldForSale	40000	usd
CY2021Q4	avrw	Goodwill Assets Held For Sale GoodwillAssetsHeldForSale	9178000	usd
CY2021Q4	avrw	Intangible Assets Net Excluding Goodwill Assets Held For Sale IntangibleAssetsNetExcludingGoodwillAssetsHeldForSale	14401000	usd
CY2021Q4	avrw	In Process Research And Development Net InProcessResearchAndDevelopmentNet	329000	usd
CY2021Q4	avrw	Other Assets Assets Held For Sale OtherAssetsAssetsHeldForSale	35000	usd
CY2021Q4	avrw	Total Assets Classified As Assets Held For Sale TotalAssetsClassifiedAsAssetsHeldForSale	26160000	usd
CY2021Q4	avrw	Accrued Utilities Current Assets Held For Sale AccruedUtilitiesCurrentAssetsHeldForSale	268000	usd
CY2021Q4	avrw	Finance Lease Liability Current Assets Held For Sale FinanceLeaseLiabilityCurrentAssetsHeldForSale	40000	usd
CY2021Q4	avrw	Deposit Contracts Liabilities Assets Held For Sale DepositContractsLiabilitiesAssetsHeldForSale	215000	usd
CY2021Q4	avrw	Total Liabilities Classified As Liabilities Held For Sale TotalLiabilitiesClassifiedAsLiabilitiesHeldForSale	523000	usd
CY2023	avrw	Product Sales Net Of Discounts And Refunds Assets Held For Sale ProductSalesNetOfDiscountsAndRefundsAssetsHeldForSale	0	usd
CY2022	avrw	Product Sales Net Of Discounts And Refunds Assets Held For Sale ProductSalesNetOfDiscountsAndRefundsAssetsHeldForSale	108000	usd
CY2023	avrw	Consulting Research Development Income Assets Held For Sale ConsultingResearchDevelopmentIncomeAssetsHeldForSale	0	usd
CY2022	avrw	Consulting Research Development Income Assets Held For Sale ConsultingResearchDevelopmentIncomeAssetsHeldForSale	58000	usd
CY2023	avrw	Shipping And Other Sales Assets Held For Sale ShippingAndOtherSalesAssetsHeldForSale	0	usd
CY2022	avrw	Shipping And Other Sales Assets Held For Sale ShippingAndOtherSalesAssetsHeldForSale	40000	usd
CY2023	avrw	Revenues Assets Held For Sale RevenuesAssetsHeldForSale	0	usd
CY2022	avrw	Revenues Assets Held For Sale RevenuesAssetsHeldForSale	206000	usd
CY2023	avrw	Cost Of Goods And Services Sold Assets Held For Sale CostOfGoodsAndServicesSoldAssetsHeldForSale	0	usd
CY2022	avrw	Cost Of Goods And Services Sold Assets Held For Sale CostOfGoodsAndServicesSoldAssetsHeldForSale	75000	usd
CY2023	avrw	Gross Profit Loss GrossProfitLoss	0	usd
CY2022	avrw	Gross Profit Loss GrossProfitLoss	131000	usd
CY2023	avrw	Research And Development Expense Assets Held For Sale ResearchAndDevelopmentExpenseAssetsHeldForSale	0	usd
CY2022	avrw	Research And Development Expense Assets Held For Sale ResearchAndDevelopmentExpenseAssetsHeldForSale	487000	usd
CY2023	avrw	Selling General And Administrative Expense Assets Held For Sale SellingGeneralAndAdministrativeExpenseAssetsHeldForSale	0	usd
CY2022	avrw	Depreciation And Amortization Assets Held For Sale DepreciationAndAmortizationAssetsHeldForSale	526000	usd
CY2023	avrw	Depreciation And Amortization Assets Held For Sale DepreciationAndAmortizationAssetsHeldForSale	0	usd
CY2022	avrw	Selling General And Administrative Expense Assets Held For Sale SellingGeneralAndAdministrativeExpenseAssetsHeldForSale	794000	usd
CY2023	avrw	Impairment Of Goodwill Assets Held For Sale ImpairmentOfGoodwillAssetsHeldForSale	0	usd
CY2022	avrw	Impairment Of Goodwill Assets Held For Sale ImpairmentOfGoodwillAssetsHeldForSale	4728000	usd
CY2023	avrw	Operating Expenses Assets Held For Sale OperatingExpensesAssetsHeldForSale	0	usd
CY2022	avrw	Operating Expenses Assets Held For Sale OperatingExpensesAssetsHeldForSale	6535000	usd
CY2023	avrw	Net Loss Before Income Taxes NetLossBeforeIncomeTaxes	0	usd
CY2022	avrw	Net Loss Before Income Taxes NetLossBeforeIncomeTaxes	-6404000	usd
CY2023	avrw	Income Tax Expense Benefit Assets Held For Sale IncomeTaxExpenseBenefitAssetsHeldForSale	0	usd
CY2022	avrw	Income Tax Expense Benefit Assets Held For Sale IncomeTaxExpenseBenefitAssetsHeldForSale	0	usd
CY2023	avrw	Net Loss NetLoss	0	usd
CY2022	avrw	Net Loss NetLoss	-6404000	usd

Files In Submission

Name	View Source	Status
0001477932-24-003092-index-headers.html	Edgar Link	pending
0001477932-24-003092-index.html	Edgar Link	pending
0001477932-24-003092.txt	Edgar Link	pending
0001477932-24-003092-xbrl.zip	Edgar Link	pending
avrw-20231231.xsd	Edgar Link	pending
avrw_10k.htm	Edgar Link	pending
avrw_ex1037.htm	Edgar Link	pending
avrw-20231231_cal.xml	Edgar Link	unprocessable
avrw-20231231_def.xml	Edgar Link	unprocessable
avrw-20231231_lab.xml	Edgar Link	unprocessable
avrw-20231231_pre.xml	Edgar Link	unprocessable
avrw_10k_htm.xml	Edgar Link	completed
avrw_ex211.htm	Edgar Link	pending
avrw_ex311.htm	Edgar Link	pending
avrw_ex312.htm	Edgar Link	pending
avrw_ex321.htm	Edgar Link	pending
avrw_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw

2024 Q2 Form 10-K Financial Statement

#000147793224003092 Filed on May 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVRW Avenir Wellness Solutions, Inc. Stock $avrw

2024 Q2 Form 10-K Financial Statement

#000147793224003092 Filed on May 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw